INOVIO PHARMACEUTICALS, INC. Payments to Acquire Short-term Investments
INOVIO PHARMACEUTICALS, INC. (INO) reported Payments to Acquire Short-term Investments of $1.98 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireShortTermInvestments · last filed 2026-08-12
- INOVIO PHARMACEUTICALS, INC. payments to acquire short-term investments for the quarter ending 2026-06-30 was -$994.54K, a 120.11% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. payments to acquire short-term investments for the quarter ending 2026-03-31 was $2.98M.
- INOVIO PHARMACEUTICALS, INC. payments to acquire short-term investments for the quarter ending 2025-12-31 was $0.00.
- INOVIO PHARMACEUTICALS, INC. payments to acquire short-term investments for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- INOVIO PHARMACEUTICALS, INC. payments to acquire short-term investments for fiscal 2025 was $4.95M, a 90.86% decline from fiscal 2024.
- INOVIO PHARMACEUTICALS, INC. payments to acquire short-term investments for fiscal 2024 was $54.14M, a 73.39% decline from fiscal 2023.
- INOVIO PHARMACEUTICALS, INC. payments to acquire short-term investments for fiscal 2023 was $203.48M, a 18.13% decline from fiscal 2022.
- INOVIO PHARMACEUTICALS, INC. payments to acquire short-term investments for fiscal 2022 was $248.53M, a 28.78% decline from fiscal 2021.
| Period end | Payments to Acquire Short-term Investments 3 month | Payments to Acquire Short-term Investments 6 month | Payments to Acquire Short-term Investments 9 month | Payments to Acquire Short-term Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$994.54K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $1.98M 10-Q · filed 2026-08-12 | $1.98M derived: sum of 3 quarters · filed 2026-08-12 | $1.98M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $2.98M 10-Q · filed 2026-05-13 | $2.98M derived: sum of 2 quarters · filed 2026-05-13 | $2.98M derived: sum of 3 quarters · filed 2026-05-13 | $7.92M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $4.95M derived: sum of 3 quarters · filed 2026-08-12 | $4.95M 10-K · filed 2026-03-12 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $4.95M derived: sum of 2 quarters · filed 2026-08-12 | $4.95M 10-Q · filed 2025-11-10 | $4.95M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $4.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $4.95M 10-Q · filed 2026-08-12 | $4.95M derived: sum of 3 quarters · filed 2026-08-12 | $29.72M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-13 | -$1.00 derived: sum of 2 quarters · filed 2026-05-13 | $24.78M derived: sum of 3 quarters · filed 2026-05-13 | $44.39M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$1.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $24.78M derived: sum of 2 quarters · filed 2026-03-12 | $44.39M derived: sum of 3 quarters · filed 2026-03-12 | $54.14M 10-K · filed 2026-03-12 |
| 2024-09-30 | $24.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $44.39M derived: sum of 2 quarters · filed 2025-11-10 | $54.14M 10-Q · filed 2025-11-10 | $83.36M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $19.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $29.36M 10-Q · filed 2025-08-12 | $58.58M derived: sum of 3 quarters · filed 2025-08-12 | $126.09M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $9.75M 10-Q · filed 2025-05-13 | $38.98M derived: sum of 2 quarters · filed 2025-05-13 | $106.48M derived: sum of 3 quarters · filed 2025-05-13 | $132.79M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $29.22M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $96.73M derived: sum of 2 quarters · filed 2025-03-18 | $123.04M derived: sum of 3 quarters · filed 2025-03-18 | $203.48M 10-K · filed 2025-03-18 |
| 2023-09-30 | $67.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $93.82M derived: sum of 2 quarters · filed 2024-11-14 | $174.25M 10-Q · filed 2024-11-14 | $219.23M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $26.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $106.74M 10-Q · filed 2024-08-08 | $151.72M derived: sum of 3 quarters · filed 2024-08-08 | $215.89M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $80.43M 10-Q · filed 2024-05-13 | $125.41M derived: sum of 2 quarters · filed 2024-05-13 | $189.58M derived: sum of 3 quarters · filed 2024-05-13 | $229.24M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $44.98M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $109.15M derived: sum of 2 quarters · filed 2024-03-06 | $148.81M derived: sum of 3 quarters · filed 2024-03-06 | $248.53M 10-K · filed 2024-03-06 |
| 2022-09-30 | $64.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $103.83M derived: sum of 2 quarters · filed 2023-11-09 | $203.55M 10-Q · filed 2023-11-09 | $244.04M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | $39.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $139.38M 10-Q · filed 2023-08-09 | $179.87M derived: sum of 3 quarters · filed 2024-03-06 | $180.47M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-03-31 | $99.72M 10-Q · filed 2023-05-10 | $140.21M derived: sum of 2 quarters · filed 2024-03-06 | $140.82M derived: sum of 3 quarters · filed 2024-03-06 | $173.27M derived: sum of 4 quarters · filed 2024-03-06 |
| 2021-12-31 | $40.49M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $41.10M derived: sum of 2 quarters · filed 2024-03-06 | $73.54M derived: sum of 3 quarters · filed 2024-03-06 | $348.95M 10-K · filed 2024-03-06 |
| 2021-09-30 | $607.85K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $33.06M derived: sum of 2 quarters · filed 2022-11-08 | $308.46M 10-Q · filed 2022-11-08 | $311.55M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $32.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $307.86M 10-Q · filed 2022-08-09 | $310.94M derived: sum of 3 quarters · filed 2023-03-01 | $325.38M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $275.41M 10-Q · filed 2022-05-10 | $278.49M derived: sum of 2 quarters · filed 2023-03-01 | $292.93M derived: sum of 3 quarters · filed 2023-03-01 | $374.93M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $3.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $17.52M derived: sum of 2 quarters · filed 2023-03-01 | $99.52M derived: sum of 3 quarters · filed 2023-03-01 | $156.22M 10-K · filed 2023-03-01 |
| 2020-09-30 | $14.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $96.44M derived: sum of 2 quarters · filed 2021-11-09 | $153.14M 10-Q · filed 2021-11-09 | $167.14M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $82.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $138.70M 10-Q · filed 2021-08-09 | $152.70M derived: sum of 3 quarters · filed 2022-03-01 | $165.95M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $56.70M 10-Q · filed 2021-05-10 | $70.70M derived: sum of 2 quarters · filed 2022-03-01 | $83.95M derived: sum of 3 quarters · filed 2022-03-01 | $92.45M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $14.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $27.25M derived: sum of 2 quarters · filed 2022-03-01 | $35.75M derived: sum of 3 quarters · filed 2022-03-01 | $100.95M 10-K · filed 2022-03-01 |
| 2019-09-30 | $13.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $21.75M derived: sum of 2 quarters · filed 2020-11-09 | $86.95M 10-Q · filed 2020-11-09 | $127.24M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $8.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $73.70M 10-Q · filed 2020-08-10 | $113.98M derived: sum of 3 quarters · filed 2021-03-01 | $130.53M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $65.20M 10-Q · filed 2020-05-11 | $105.48M derived: sum of 2 quarters · filed 2021-03-01 | $122.03M derived: sum of 3 quarters · filed 2021-03-01 | $143.79M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $40.29M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $56.84M derived: sum of 2 quarters · filed 2021-03-01 | $78.59M derived: sum of 3 quarters · filed 2021-03-01 | $88.16M 10-K · filed 2021-03-01 |
| 2018-09-30 | $16.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $38.30M derived: sum of 2 quarters · filed 2019-11-12 | $47.87M 10-Q · filed 2019-11-12 | $61.30M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-06-30 | $21.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $31.32M 10-Q · filed 2019-08-08 | $44.75M derived: sum of 3 quarters · filed 2020-03-12 | $112.42M derived: sum of 4 quarters · filed 2020-03-12 |
| 2018-03-31 | $9.57M 10-Q · filed 2019-05-09 | $23.00M derived: sum of 2 quarters · filed 2020-03-12 | $90.67M derived: sum of 3 quarters · filed 2020-03-12 | $99.34M derived: sum of 4 quarters · filed 2020-03-12 |
| 2017-12-31 | $13.43M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $81.10M derived: sum of 2 quarters · filed 2020-03-12 | $89.77M derived: sum of 3 quarters · filed 2020-03-12 | $95.70M 10-K · filed 2020-03-12 |
| 2017-09-30 | $67.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $76.34M derived: sum of 2 quarters · filed 2018-11-08 | $82.27M 10-Q · filed 2018-11-08 | $97.09M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-06-30 | $8.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $14.60M 10-Q · filed 2018-08-07 | $29.42M derived: sum of 3 quarters · filed 2019-03-12 | $43.93M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-03-31 | $5.93M 10-Q · filed 2018-05-09 | $20.75M derived: sum of 2 quarters · filed 2019-03-12 | $35.26M derived: sum of 3 quarters · filed 2019-03-12 | $51.08M derived: sum of 4 quarters · filed 2019-03-12 |
| 2016-12-31 | $14.82M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $29.33M derived: sum of 2 quarters · filed 2019-03-12 | $45.15M derived: sum of 3 quarters · filed 2019-03-12 | $57.32M 10-K · filed 2019-03-12 |
| 2016-09-30 | $14.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $30.33M derived: sum of 2 quarters · filed 2017-11-08 | $42.50M 10-Q · filed 2017-11-08 | $68.63M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-06-30 | $15.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $27.99M 10-Q · filed 2017-08-08 | $54.12M derived: sum of 3 quarters · filed 2018-03-14 | $56.32M derived: sum of 4 quarters · filed 2018-03-14 |
| 2016-03-31 | $12.16M 10-Q · filed 2017-05-10 | $38.30M derived: sum of 2 quarters · filed 2018-03-14 | $40.50M derived: sum of 3 quarters · filed 2018-03-14 | $70.70M derived: sum of 4 quarters · filed 2018-03-14 |
| 2015-12-31 | $26.13M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $28.33M derived: sum of 2 quarters · filed 2018-03-14 | $58.54M derived: sum of 3 quarters · filed 2018-03-14 | $63.53M 10-K · filed 2018-03-14 |
| 2015-09-30 | $2.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $32.40M derived: sum of 2 quarters · filed 2016-11-09 | $37.39M 10-Q · filed 2016-11-09 | $65.29M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-06-30 | $30.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $35.19M 10-Q · filed 2016-08-08 | $63.09M derived: sum of 3 quarters · filed 2017-03-15 | $74.09M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-03-31 | $4.99M 10-Q · filed 2016-05-09 | $32.89M derived: sum of 2 quarters · filed 2017-03-15 | $43.89M derived: sum of 3 quarters · filed 2017-03-15 | $46.18M derived: sum of 4 quarters · filed 2017-03-15 |
| 2014-12-31 | $27.90M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $38.90M derived: sum of 2 quarters · filed 2017-03-15 | $41.19M derived: sum of 3 quarters · filed 2017-03-15 | $47.19M 10-K · filed 2017-03-15 |
| 2014-09-30 | $11.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $13.29M derived: sum of 2 quarters · filed 2015-11-09 | $19.29M 10-Q · filed 2015-11-09 | $29.00M derived: sum of 4 quarters · filed 2016-03-14 |
| 2014-06-30 | $2.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $8.29M 10-Q · filed 2015-08-10 | $17.99M derived: sum of 3 quarters · filed 2016-03-14 | $17.99M derived: sum of 4 quarters · filed 2016-03-14 |
| 2014-03-31 | $6.00M 10-Q · filed 2015-05-11 | $15.71M derived: sum of 2 quarters · filed 2016-03-14 | $15.71M derived: sum of 3 quarters · filed 2016-03-14 | $21.00M derived: sum of 4 quarters · filed 2016-03-14 |
| 2013-12-31 | $9.71M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | $9.71M derived: sum of 2 quarters · filed 2016-03-14 | $15.00M derived: sum of 3 quarters · filed 2016-03-14 | $15.40M 10-K · filed 2016-03-14 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | $5.29M derived: sum of 2 quarters · filed 2014-11-10 | $5.69M 10-Q · filed 2014-11-10 | $7.19M derived: sum of 4 quarters · filed 2015-03-16 |
| 2013-06-30 | $5.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $5.69M 10-Q · filed 2014-08-11 | $7.19M derived: sum of 3 quarters · filed 2015-03-16 | $8.52M derived: sum of 4 quarters · filed 2015-03-16 |
| 2013-03-31 | $400.00K 10-Q · filed 2014-05-12 | $1.90M derived: sum of 2 quarters · filed 2015-03-16 | $3.22M derived: sum of 3 quarters · filed 2015-03-16 | $6.43M derived: sum of 4 quarters · filed 2015-03-16 |
| 2012-12-31 | $1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $2.82M derived: sum of 2 quarters · filed 2015-03-16 | $6.03M derived: sum of 3 quarters · filed 2015-03-16 | $9.14M 10-K · filed 2015-03-16 |
| 2012-09-30 | $1.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | $4.53M derived: sum of 2 quarters · filed 2013-11-12 | $7.64M 10-Q · filed 2013-11-12 | $20.07M derived: sum of 4 quarters · filed 2014-03-17 |
| 2012-06-30 | $3.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $6.32M 10-Q · filed 2013-08-09 | $18.74M derived: sum of 3 quarters · filed 2014-03-17 | $18.75M derived: sum of 4 quarters · filed 2014-03-17 |
| 2012-03-31 | $3.11M 10-Q · filed 2013-05-10 | $15.53M derived: sum of 2 quarters · filed 2014-03-17 | $15.54M derived: sum of 3 quarters · filed 2014-03-17 | $17.64M derived: sum of 4 quarters · filed 2014-03-17 |
| 2011-12-31 | $12.43M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-17 | $12.43M derived: sum of 2 quarters · filed 2014-03-17 | $14.53M derived: sum of 3 quarters · filed 2014-03-17 | $18.19M 10-K · filed 2014-03-17 |
| 2011-09-30 | $2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-07 | $2.10M derived: sum of 2 quarters · filed 2012-11-07 | $5.77M 10-Q · filed 2012-11-07 | $5.76M derived: sum of 4 quarters · filed 2013-03-18 |
| 2011-06-30 | $2.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | $5.77M 10-Q · filed 2012-08-09 | $5.76M derived: sum of 3 quarters · filed 2013-03-18 | $5.77M derived: sum of 4 quarters · filed 2013-03-18 |
| 2011-03-31 | $3.67M 10-Q · filed 2012-05-09 | $3.66M derived: sum of 2 quarters · filed 2013-03-18 | $3.67M derived: sum of 3 quarters · filed 2013-03-18 | |
| 2010-12-31 | -$9.93K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $0.00 derived: sum of 2 quarters · filed 2013-03-18 | $8.00M 10-K · filed 2013-03-18 | |
| 2010-09-30 | $9.93K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-07 | $8.01M 10-Q · filed 2011-11-07 | ||
| 2010-06-30 | $8.00M 10-Q · filed 2011-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |